FogPharma® Announces $107 Million Series C Financing to Advance Direct β-Catenin Antagonist and Universal Druggability™ Platform
March 01, 2021 07:00 AM Eastern Standard Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–FogPharma®, a biopharmaceutical company pioneering a new class of precision medicines potentially applicable to all therapeutic targets, including those previously considered “undruggable”, today announced the Company’s $107 million Series C financing. The financing was led by venBio Partners, with participation from new investors Cormorant Asset […]
Artiva Biotherapeutics Raises $120 Million in Series B Financing to Advance Pipeline of Allogeneic NK Cell Therapies
SAN DIEGO, February 26, 2021 — Artiva Biotherapeutics, Inc., an oncology-focused biopharmaceutical company developing cell therapies based on primary allogeneic natural killer (NK) cells that have been optimized for their ability to kill tumors, today announced the closing of a $120 million Series B financing. New investor Venrock Healthcare Capital Partners led the financing. Other new […]
Artiva Biotherapeutics Announces Exclusive Worldwide Collaboration and License Agreement with Merck to Develop Candidate CAR-NK Cell Therapies
Collaboration utilizes Artiva’s proprietary off-the-shelf allogeneic NK cell and CAR technology platforms to develop up to three CAR-NK cell therapies targeting solid tumor-associated antigens
Artiva to receive $30 million upfront payment and up to $612 million per program in potential future development and commercial milestones, and royalties on any future worldwide product sales
Artiva to develop novel CAR-NK cell therapy candidates and transfer to Merck for clinical development and commercialization
Positive Phase 2b ICONA Interim Results for icosabutate in NASH Patients
Icosabutate demonstrates potent anti-inflammatory, anti-fibrotic and antioxidant properties, and shows improvement in cardio-metabolic risk profile January 08, 2021 03:00 AM Eastern Standard Time AMSTERDAM–(BUSINESS WIRE)–NorthSea Therapeutics B.V., (‘NST’) a Dutch biotech company developing novel and innovative therapies for NASH (Non-alcoholic Steatohepatitis) and other metabolic, inflammatory, and fibrotic diseases based on its SEFA (Structurally Engineered Fatty […]
Artiva Biotherapeutics Announces Appointment of Dr. Fred Aslan as President and CEO
SAN DIEGO–(BUSINESS WIRE)—Artiva Biotherapeutics, Inc., an oncology company focused on developing and commercializing primary allogeneic natural killer (NK) cell therapies to treat cancer, announced today the appointment of Fred Aslan, M.D., as President and Chief Executive Officer. Dr. Aslan brings a twenty-year track record as an executive and investor in the life sciences industry.
Barely two months after unveiling a new breed of radiopharmaceuticals, RayzeBio brings total haul to $150M
Just before Versant and venBio officially took the wraps off RayzeBio with $45 million in launch money, Ken Song reached out to a few other investors “just to give them an overview.” He wasn’t necessarily looking to raise money immediately, the CEO said. Whereas the Series A came together mostly around the concept of a […]
Tallac Therapeutics Launches with $62 Million in Series A Financing to Advance Novel Immunotherapies for Cancer
~ Company Founded by Experienced Leaders with Track Record of Developing Successful Next-Generation Medicines for Cancer ~ December 01, 2020 07:00 AM Eastern Standard Time BURLINGAME, Calif.–(BUSINESS WIRE)–Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced the completion of its Series A financing […]
Pharvaris Announces $80 Million Series C Financing to Advance Novel Oral Bradykinin-B2-Receptor Antagonists for the Treatment of HAE
Zug, Switzerland, Nov. 18, 2020 – Pharvaris, a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced the close of its oversubscribed $80 million Series C financing bringing its total venture funding to over $160 million to date. Viking Global Investors and General […]
Elevation Oncology Announces $65M Series B Financing and Promotion of Founder Shawn M. Leland to Chief Executive Officer
– $65M Series B Raise Led by New Investors venBio Partners and Cormorant Asset Management, with Participation by Boxer Capital of Tavistock Group, Janus Henderson, Samsara Biocapital, Vivo Capital, and All Existing Series A Investors – – Shawn M. Leland, Founder of Elevation Oncology, Named Chief Executive Officer; Steve Elms, Managing Partner of Aisling Capital, […]
Pharvaris Presents Clinical Data at ACAAI 2020 Demonstrating Safety and Therapeutic Potential of Oral PHA121 for the Treatment of HAE
PHA121 outperforms icatibant in a bradykinin-challenge study Zug, Switzerland, Nov. 13, 2020 – Pharvaris, a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, announced the presentation of two posters at the virtual American College of Asthma, Allergy and Immunology (ACAAI) Annual […]
